Freshly minted as a "unicorn," the Utah healthcare data analytics powerhouse is building up a new life sciences division to aid biotech development and precision medicine.
Researchers used the system to improve a method for analyzing lymph nodes and believe it could improve the care of patients with these and other early-stage cancers.
A report from the Personalized Medicine Coalition finds that more than 40 percent of new drugs approved in the US in 2018 were personalized medicines.
The company is working with partners to identify new biomarkers and treatments as well as to collect utility evidence for its current coaching model.
The institutes will send patients samples to Resolution Bioscience, which will sequence circulating tumor DNA to identify the genetic causes of drug resistance.
The company believes that helping to funnel patients to the trial will help support its own goals to gather genomic information on targeted cancer therapy efficacy.
In a small study, melanoma patients with BRAF V600K mutations responded better to immunotherapy while those with V600E mutations had a better response to targeted therapy.
After a successful pilot that recruited 1,000 patients, NorthShore will now engage 10,000 people to receive Color's genomic testing in their primary care.
Researchers have developed a new Alzheimer's disease mouse model with greater genetic diversity.
The government has also pledged €5 million from the European Regional Development Fund to support the integration of genetic data into routine medical care.
Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.
New Scientist reports that 20 percent of human and yeast proteins are uncharacterized.
The University of Zurich's Ruedi Aebersold and his colleagues analyzed a dozen HeLa cell lines to find differences in gene expression, protein levels, and more.
In Nature this week: protein-coding variants associated with body-fat distribution, and more.